Literature DB >> 25511516

A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines.

Kaalin Gopaul, Suhas A Shintre, Neil A Koorbanally1.   

Abstract

Quinolines substituted at C-2 on the quinoline scaffold have shown interesting anticancer activity in a number of anticancer assays such as breast (MCF-7, MDA-MB 231), human cervical epithelioid (HeLa), oral squamous cell carcinoma (SAS), human stomach adenocarcinoma (AGS, MKN45), hepatocellular (SKHep, HepG-2, Hep-3B), prostate (PC-3, DU145), lung (A549, H-460), gastric (HGC, MNK-74), leukemia (K562, U937, REH, NALM6, CEM/ADR 5000), colon (Colo-205, HCT 116, SW620, Caco-2, HT29), neuroblastoma (IMR32), CNS (SF-268), oesophageal (EAC) and melanoma (A-375). They have been synthesised by a number of strategies starting with isatin, anilines, nitrobenzenes and benzamides and some even with cyclohexanone and cyclohexa-1,3-diones with ammonium acetate. Many of the synthetic strategies employ the derivatisation of quinoline precursors itself. We review here the synthesis of 145 bioactive anticancer quinolines substituted at the 2-position and their anticancer activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25511516     DOI: 10.2174/1871520615666141216125446

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  2 in total

1.  Acid-promoted iron-catalysed dehydrogenative [4 + 2] cycloaddition for the synthesis of quinolines under air.

Authors:  Jinfei Yang; Xiao Meng; Kai Lu; Zhihao Lu; Minliang Huang; Chengniu Wang; Fei Sun
Journal:  RSC Adv       Date:  2018-09-10       Impact factor: 4.036

2.  An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells.

Authors:  Min-Wu Chao; Han-Li Huang; Wei-Chun HuangFu; Kai-Cheng Hsu; Yi-Min Liu; Yi-Wen Wu; Chao-Feng Lin; Yi-Lin Chen; Mei-Jung Lai; Hsueh-Yun Lee; Jing-Ping Liou; Che-Ming Teng; Chia-Ron Yang
Journal:  Oncotarget       Date:  2017-04-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.